NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Biodexa Pharmaceuticals Plc (BDRX) Stock Analysis

Biodexa Pharmaceuticals Plc (BDRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BDRX

$0.42

+$0.03 (+8.92%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BDRX with… →

BDRX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.40
Previous Close
$0.39
Day's Range
0.38–0.44
52-Week Range
0.34–44.70
Volume
223.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.28
Valuation
Market Cap
$849.73K
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.38M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.20M
1-Year Return
−98.89%
Dividend and dates
Avg Volume
4.98M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BDRX closed at $0.42, −98.89% over 1 year.

Biodexa Pharmaceuticals Plc (BDRX) has a market capitalization of $849.73K.

In fiscal 2025, BDRX reported revenue of $0.00.

BDRX Stock Return by Calendar Year

Biodexa Pharmaceuticals Plc (BDRX) return since Jan 2025: what $10,000 became

1 year
$10,000 $111
−98.89%
Since Jan 2025
$10,000 $19
−99.81%

If you had invested $10,000 in Biodexa Pharmaceuticals Plc (BDRX) at the close on January 10, 2025, the earliest close on record here, it would have been worth $19 at the close on October 21, 2026: −99.81% in total, −97.10% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−96.30%
2025−94.98%

As of October 21, 2026.

BDRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.38M—
2024$0.00−$5.73M—
2023$381.00K−$7.08M−1,858.0%
2022$699.00K−$7.66M−1,095.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00−$3.96M−$8.65M−$6.38M—
2024$0.00−$5.44M−$9.20M−$5.73M—
2023$381.00K−$3.69M−$8.01M−$7.08M−1,858.0%
2022$699.00K−$4.41M−$8.93M−$7.66M−1,095.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Biodexa Pharmaceuticals Plc (BDRX) at $849.73K. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 11.

BDRX last closed at $0.42 on October 21, 2026. That is +$0.03 (+8.92%) against the previous close. Over the past 52 weeks the price has ranged from $0.34 to $44.70. The latest close sits 24.6% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $6.38M.

Across the 4 fiscal years on file, revenue moves from $699.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The reported beta is 1.28. Daily returns over the trailing 1 year annualize to a volatility of 203.69%. The trailing one-year total return is −98.89%. The stored price history starts on January 10, 2025, and the total return since then is −99.81%.

Growth & Income

No dividend is on file for BDRX.

So far in 2026 the total return is −96.30%. The record holds one complete calendar year, 2025, which returned −94.98%.

Peer Comparison

Biodexa Pharmaceuticals Plc (BDRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biodexa Pharmaceuticals Plc BDRX $849.73K —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Visit website →